Clinically applicable CD34


Journal

Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 20 10 2020
accepted: 22 02 2021
pubmed: 3 4 2021
medline: 16 10 2021
entrez: 2 4 2021
Statut: ppublish

Résumé

Allogeneic stem cell transplantation (alloSCT), following induction chemotherapy, can be curative for hemato-oncology patients due to powerful graft-versus-tumor immunity. However, disease recurrence remains the major cause of treatment failure, emphasizing the need for potent adjuvant immunotherapy. In this regard, dendritic cell (DC) vaccination is highly attractive, as DCs are the key orchestrators of innate and adaptive immunity. Natural DC subsets are postulated to be more powerful compared with monocyte-derived DCs, due to their unique functional properties and cross-talk capacity. Yet, obtaining sufficient numbers of natural DCs, particularly type 1 conventional DCs (cDC1s), is challenging due to low frequencies in human blood. We developed a clinically applicable culture protocol using donor-derived G-CSF mobilized CD34

Identifiants

pubmed: 33796917
doi: 10.1007/s00262-021-02899-3
pii: 10.1007/s00262-021-02899-3
pmc: PMC8505305
doi:

Substances chimiques

Antigens, CD34 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3167-3181

Subventions

Organisme : KWF Kankerbestrijding
ID : 10351
Organisme : KWF Kankerbestrijding
ID : 11079
Organisme : Health-Holland Foundation
ID : LSHM18048

Informations de copyright

© 2021. The Author(s).

Références

Methods Mol Biol. 2016;1423:19-37
pubmed: 27142006
Cancer Res. 2013 Feb 1;73(3):1063-75
pubmed: 23345163
Science. 2017 Apr 21;356(6335):
pubmed: 28428369
J Exp Med. 2010 Jun 7;207(6):1273-81
pubmed: 20479115
J Exp Med. 2010 Jun 7;207(6):1247-60
pubmed: 20479116
Cancer Res. 2017 Dec 15;77(24):7059-7071
pubmed: 29042417
Nature. 2019 Oct;574(7776):45-56
pubmed: 31578484
Biol Blood Marrow Transplant. 2017 Aug;23(8):1241-1249
pubmed: 28495640
Biol Blood Marrow Transplant. 2009 May;15(5):580-8
pubmed: 19361750
Oncoimmunology. 2017 Feb 6;6(3):e1285991
pubmed: 28405517
J Immunother Cancer. 2019 Apr 18;7(1):109
pubmed: 30999964
Leukemia. 2007 Oct;21(10):2145-52
pubmed: 17673900
Clin Cancer Res. 2016 May 1;22(9):2155-66
pubmed: 26712687
Front Immunol. 2019 May 09;10:1014
pubmed: 31143179
Front Immunol. 2015 Mar 23;6:129
pubmed: 25852695
Nature. 1992 Dec 10;360(6404):593-7
pubmed: 1281285
Haematologica. 2011 Mar;96(3):477-81
pubmed: 21109688
Immunology. 2012 Jun;136(2):163-75
pubmed: 22260486
Stem Cells Dev. 2014 May 1;23(9):955-67
pubmed: 24325394
Blood. 2004 Nov 15;104(10):3267-75
pubmed: 15242871
J Immunol. 2016 Feb 15;196(4):1711-20
pubmed: 26792804
Blood. 2009 Mar 26;113(13):3119-29
pubmed: 18945967
J Immunol. 2019 Jan 15;202(2):451-459
pubmed: 30559321
Nature. 2001 May 17;411(6835):385-9
pubmed: 11357147
J Immunol. 2007 Feb 1;178(3):1534-41
pubmed: 17237402
Lancet Oncol. 2014 Jun;15(7):e257-67
pubmed: 24872109
J Exp Med. 2010 Jun 7;207(6):1261-71
pubmed: 20479117
Immunity. 2017 Feb 21;46(2):205-219
pubmed: 28190711
Blood. 2015 May 14;125(20):3173-82
pubmed: 25769621
J Exp Med. 2013 Nov 18;210(12):2515-22
pubmed: 24145513
Cell Rep. 2018 Jun 19;23(12):3658-3672.e6
pubmed: 29925006
Front Immunol. 2019 Jun 11;10:1325
pubmed: 31244860
Front Immunol. 2018 Jul 16;9:1643
pubmed: 30061897
Br J Haematol. 2008 Sep;142(6):877-88
pubmed: 18564358
J Exp Med. 2010 Jun 7;207(6):1283-92
pubmed: 20479118
Cell. 2015 Sep 10;162(6):1322-37
pubmed: 26296422
Oncoimmunology. 2018 Aug 6;7(10):e1488565
pubmed: 30288356
Leuk Res. 2012 Jun;36(6):699-703
pubmed: 22172462
Blood. 2012 Mar 8;119(10):2284-92
pubmed: 22234694
Immunity. 2007 Apr;26(4):503-17
pubmed: 17398124
J Immunol. 2015 Nov 15;195(10):4810-21
pubmed: 26453750
J Immunol. 2014 Aug 15;193(4):1622-35
pubmed: 25009205
Cell Rep. 2018 Aug 14;24(7):1902-1915.e6
pubmed: 30110645
Cell Mol Life Sci. 2011 Nov;68(21):3505-18
pubmed: 21861182
Immunity. 2019 Jan 15;50(1):37-50
pubmed: 30650380
Immunology. 2018 May;154(1):3-20
pubmed: 29313948
Mol Cancer. 2020 Aug 6;19(1):120
pubmed: 32762681
Anticancer Agents Med Chem. 2015;15(3):327-35
pubmed: 25322987
Cancer Immunol Immunother. 2018 Sep;67(9):1425-1436
pubmed: 30019146
Genome Biol. 2008 Jan 24;9(1):R17
pubmed: 18218067
Nat Rev Immunol. 2018 Oct;18(10):635-647
pubmed: 30057419
Blood. 2009 Jul 23;114(4):835-43
pubmed: 19465690

Auteurs

Jesper van Eck van der Sluijs (J)

Department of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 8, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.

Diede van Ens (D)

Department of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 8, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.

Soley Thordardottir (S)

Department of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 8, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.

Denise Vodegel (D)

Department of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 8, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.

Inge Hermens (I)

Department of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 8, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.

Anniek B van der Waart (AB)

Department of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 8, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.

J H Frederik Falkenburg (JHF)

Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.

Michel G D Kester (MGD)

Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.

Iris de Rink (I)

Genomics Core Facility, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Mirjam H M Heemskerk (MHM)

Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.

Jannie Borst (J)

Department of Immunology and Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.

Nicolaas P M Schaap (NPM)

Department of Hematology, Radboud University Medical Center, Nijmegen, The Netherlands.

Joop H Jansen (JH)

Department of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 8, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.

Yanling Xiao (Y)

Department of Immunology and Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.

Harry Dolstra (H)

Department of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 8, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands.

Willemijn Hobo (W)

Department of Laboratory Medicine, Laboratory of Hematology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Geert Grooteplein 8, P.O. Box 9101, 6500 HB, Nijmegen, The Netherlands. Willemijn.Hobo@radboudumc.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH